Gilead Sciences (GILD) Net Income towards Common Stockholders (2009 - 2026)

Gilead Sciences has reported Net Income towards Common Stockholders for 18 years, with the latest figure at $2.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 53.69% year-over-year to $2.0 billion; the trailing twelve-month figure through Mar 2026 stood at $9.6 billion (up 60.3% YoY), and the FY2025 full-year result was $8.5 billion, up 1676.62% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at $2.0 billion, down from $2.5 billion in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $3.1 billion in Q3 2025, with the low at -$4.2 billion in Q1 2024.
• Historically, Net Income towards Common Stockholders has averaged $1.3 billion across 5 years, with a median of $1.6 billion in 2024.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders jumped 8100.0% — and 2024, when it slumped 523.88%.
• Gilead Sciences' Net Income towards Common Stockholders stood at $1.6 billion in 2022, then dropped by 13.29% to $1.4 billion in 2023, then advanced by 25.85% to $1.8 billion in 2024, then soared by 41.86% to $2.5 billion in 2025, then dropped by 20.06% to $2.0 billion in 2026.
• The last three Net Income towards Common Stockholders figures came in at $2.0 billion (Q1 2026), $2.5 billion (Q4 2025), and $3.1 billion (Q3 2025), per Business Quant data.